In Brazil, little data exist regarding the distribution of genotypes in relation to basal core promoter (BCP) and precore/core mutations among chronic hepatitis B virus (HBV) carriers from different regions of the country. The aim of this study was to identify HBV genotypes and the frequency of mutations at the BCP and precore/core region among the prevalent genotypes in chronic carriers from southern Brazil. Methods: Nested-polymerase chain reaction (nested-PCR) products amplifi ed from the S-polymerase gene, BCP and precore/core region from 54 samples were sequenced and analyzed. Results: Phylogenetic analysis of the S-polymerase gene sequences showed that 66.7% (36/54) of the patients were infected with genotype D (D1, D2, D3), 25.9% (14/54) with genotype A (A1, A2), 5.6% (3/54) with subgenotype C2, and 2% (1/54) with genotype E. A comparison of virological characteristics showed signifi cant differences between genotypes A, C and D. The comparison between HBeAg status and the G1896A stop codon mutation in patients with genotype D revealed a relationship between HBV G1896A precore mutants and genotype D and hepatitis B e antigen (HBeAg) seroconversion. Genotype D had a higher prevalence of the G1896A mutation and the presence of a thymine at position 1858. Genotype A was associated with a higher prevalence of the G1862T mutation and the presence of a cytosine at position 1858. Conclusions: HBV genotype D (D3) is predominant in HBV chronic carriers from southern Brazil. The presence of mutations in the BCP and precore/core region was correlated with the HBV genotype and HBeAg negative status.
Infection with hepatitis B virus (HBV) is an important worldwide cause of morbidity and mortality, especially in developing countries [1] [2] [3] . In Brazil, approximately15% of the population has been in contact with HBV, and 1 to 3% of the population is chronically infected 4 . Persistent infection with HBV is intimately associated with the development of cirrhosis and hepatocellular carcinoma (HCC), and HBV is the primary cause of acute and chronic liver disease, causing 1 million deaths per year 5 .
Hepatitis B virus is currently classifi ed into nine genotypes (A-I) that are defi ned based on intergroup differences of more than 8% in the complete genome sequence and of more than 4% in the S gene with genotypes F and H being the most divergent [6] [7] [8] . Epidemiological studies have shown that each genotype is characterized by a distinct geographic and ethnic distribution 9 . In brief, genotype A is prevalent in northwestern Europe, North America and Africa 6, 10, 11 . Genotypes B and C are commonly found in Asia 7, [9] [10] [11] , whereas genotype D shows a worldwide distribution but predominates in the Mediterranean region, including the Middle East and central Asia [10] [11] [12] . Genotype E is found in the Western region of Africa 10, 13, 14 , genotype F is present in the aboriginal population of South America, and genotype H is confi ned to Central America. Genotype G was initially isolated from HBV carriers in France and Georgia (United States) 8 and was later detected in the United Kingdom 11 , Italy 11 and Germany 15 . Recently, HBV genotype I was described in northwestern China, Vietnam and Laos 16, 17 . Finally, a recently identifi ed tenth genotype provisionally assigned as genotype J was proposed for a HBV isolate from a Japanese patient www.scielo.br/rsbmt I www.rsbmt.org.br Mello 
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with HCC 18 . Previous studies have shown that A, D and F are the primary genotypes circulating in Brazil 19, 20 .Furthermore, phylogenetic studies have demonstrated that the A, B, C, D and F HBV genotypes can be subdivided into subgenotypes. Evidence indicates that genotypes and associated subgenotypes differ in virological characteristics that may be related to differences in the clinical evolution of liver disease and response to treatment 21 . The occurrence of various mutations in the HBV genome during the course of persistent viral infection has been reported, and increasing evidence of an association between molecular changes (mainly in the precore gene and the basal core promoter region) and the development of HCC in patients infected with HBV has been described 22 .
Studies have demonstrated a correlation between HBV genotypes and the development of mutations in the precore gene and in the basal core promoter (BCP) region 1, 10, 23 . The wellknown naturally occurring HBV variants include the precore stop codon mutation (G1896A), which abolishes hepatitis B e antigen (HBeAg) production and serves to enhance the stability of the secondary structure of the pre-genome encapsidation signal, favoring the maintenance of viral replication [23] [24] [25] . The other common HBV variants include double mutations in the BCP region (A1762T/G1764A), which occur in a regulatory region [25] [26] [27] . Apart from these variants, other mutations such as T1753V in the BCP region, G1899A in the precore region and G1862T in the precore region have been identifi ed and are associated with HCC development, HBeAg production and the reverse transcription process, respectively 1, [28] [29] [30] [31] [32] [33] [34] [35] . The identifi cation of patients presenting with risk factors for the development of advanced liver disease such as HCC among chronic hepatitis B carriers is important. Many clinical and virological factors potentially associated with an increased risk of HCC have been identifi ed 36 such as male gender and advanced age 37 , virological factors such as HBeAg positivity, elevated serum levels of viral deoxyribonucleic acid (DNA), genotype and mutations in the BCP and precore/core gene 38 , and clinical liver disease factors such as enzyme levels (alanine aminotransferase) and the presence of cirrhosis 36, 39 .
In Brazil, a geographically large country with a history of intense heterogeneous migration, little data exist regarding the distribution of genotypes in relation to BCP and precore/ core mutations available from different regions of the country. Thus, the objective of the present study was to investigate the molecular characteristics of HBV in chronic carriers from a region located in southern Brazil to identify HBV genotypes and the frequency of mutation at the BCP and the precore/core region among the prevalent genotypes.
Patients
This study included samples collected between 2007 and 2008 from 71 patients chronically infected with HBV. These patients were from the northwestern region of the State of Paraná located in southern Brazil.
The patients were under medical assistance at the Hepatitis Outpatient Clinic of the Consórcio Intermunicipal de Saúde do Setentrião Paranaense (CISAMUSEP). The serum was separated from 10-ml blood samples, and the samples were stored in two aliquots at -20ºC and thawed immediately prior to the tests.
The data regarding the stage of infection, gender, age, HBeAg status, and blood levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) classified as normal or elevated (when higher than two times the upper limit of normal) were obtained from the patient records.
Detection of HBV DNA by PCR
Hepatitis B virus deoxyribonucleic acid was extracted using phenol-chloroform 40 followed by ethanol precipitation. HBV DNA was amplifi ed by nested polymerase chain reaction (nested-PCR) using previously described primers. For the BCP and precore/core regions, the EP1.1/2032 (fi rst round) and EP2.1/2017R (second round) primers yielded a 501-bp fragment 34, 41 . The PCR was conducted in a thermocycler (Techne TC-512, Techne Inc, NJ, USA) under the following conditions: initial denaturation at 94ºC for 1min; followed by 30 cycles at 94ºC for 1min, 45.5ºC for 1min and 72ºC for 1min; and a fi nal extension step at 72ºC for 5min.
The S-polymerase (S-Pol) gene was amplified using the FHBS1/RADE1 (first round) and FHBS2/RADE2 (second round) primers, yielding a 734-bp fragment 20, 42 . The amplifi cation conditions for the S-Pol gene only differed in terms of the annealing temperature, which was 56ºC in the fi rst step and 50ºC in the second step: initial denaturation at 94ºC for 1min; followed by 34 cycles at 94ºC for 30s, 56/50ºC for 30s and 72ºC for 30s; with a fi nal extension step at 72ºC for 7min.The PCR products were separated by electrophoresis on a 1% agarose gel, stained with ethidium bromide and observed under ultraviolet light.
Sequencing
After purification, the PCR products were sequenced according to a previously described method 43 using the EP2.1 and 2017R primers for the BCP and the precore/core region and FHBS2, RHBS2, 5'LAM5 44 and RADE2 primers for S-Pol with fl uorescent-labeled dideoxynucleotides (ddNTPs) using the ABI Prism® BigDyeTM Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA). After precipitation and purifi cation of the reaction product, the samples were denatured and sequenced in an automatic ABI 3100 sequencer (Applied Biosystems).
Sequence analysis
The sequences obtained were fi rst analyzed using the PhredPhrap program (http://asparagin.cenargen.embrapa.br/phph/) to determine the data quality and construction of the consensus sequence using nucleotide bases with a score > 20. Genotyping and analysis of the BCP and precore mutants were performed by comparison of the sequences obtained with the sequences of different HBV genotypes previously published in GenBank. The accession numbers of the sequences used are shown in Clustal X, version 2.0.9 46 programs were used for sequence analysis and editing. Phylogenetic analysis was performed with the Mega 4 (Molecular Evolutionary Genetics Analysis) package 47 . The aligned dataset of S-Pol gene sequences were analyzed by the neighbor-joining method. Genetic distances were calculated using Kimura's two-parameter model. Bootstrap analysis with 1,000 replicates was performed to test the reliability of the tree with values ≥ 70 indicated on the branches.
Statistical analysis
All data were analyzed using the Statistica 8.0 48 and SAS version 9.1.3 49 packages. Fisher's exact test was used to compare categorical variables. Continuous data were compared by analysis of variance (ANOVA) and the Student t-test. A p value < 0.05 was considered statistically signifi cant.
GenBank accession numbers
The sequences were deposited in GenBank under the accession numbers FJ865506 to FJ865559 (S-Pol gene) and FJ969215 to FJ969268 (BCP and precore/core gene).
Ethical considerations
The study was approved by the Ethics Committee on Human Research of Universidade Estadual de Maringá, and each patient signed a free informed consent form (CAAE Number 0181.0.093.000-06; protocol 319/2006).
HBV Genotyping
Hepatitis B virus deoxyribonucleic acid was detected in plasma samples from 56 (79%) of the 71 patients included in this study. However, the BCP, precore/core and S-Pol gene regions could only be sequenced in 54 (76%) samples. These 54 patients had a mean age of 42 ± 12.9 years, and 30 (55.6%) were males and 24 (44.4%) were females.
Phylogenetic analysis of the S-Pol region revealed welldefi ned clusters and statistical signifi cance for all genotypes with a bootstrap result higher than 89% for the main branches (Figure 1 ). Thirty-six (66.7%) of the 54 patients were infected with genotype D, 14 (25.9%) with genotype A, three (5.6%) with genotype C, and one (1.8%) with genotype E. The subgenotypes identifi ed in the present study are displayed in Figure 1 , and the frequency of HBV genotypes and subgenotypes in the 54 patients studied is shown in Figure 2 .
No signifi cant differences in clinical and demographic characteristics [age, gender, HBeAg positivity rate and altered serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels] were observed in patients infected with the HBV genotypes A, C and D (Table 1) . Data from the only patient infected with genotype E are not listed in Table 2 , but he was male, 29 years old, had normal levels of ALT and AST, was HBeAg negative, and the virus had the G1896A stop codon mutation and a T at position 1858. Analysis of the BCP and precore/core sequences in the 54 samples showed that the G1896A precore mutation was the most frequent (30/54, 55.6%) followed by the BCP double mutation A1762T/G1764A (22/54, 40.7%), the BCP T1753V mutation (18/54, 33.3%) and the G1899A (14/54, 26%) and G1862T (11/54, 20 .4%) precore region mutations. All 30 samples identifi ed as G1896A mutants had a thymine (T) at position 1858, 83.3% (15/18) of the T1753V mutants had the BCP double mutation, and 9 samples (16.6% -9/54) carried all these mutations simultaneously.
Comparison of the virological characteristics showed signifi cant differences between genotypes A, C and D, especially in terms of the G1896A and G1862T mutations and the presence of a thymine at position 1858 (p< 0.001). Comparison of genotypes A, C and D showed a lower frequency of the A1762T/G1764A mutation in genotype D samples, whereas the G1896A mutation was the most frequent in this genotype (p< 0.001) ( Table 1) .
Among the genotypes identifi ed, genotype A presented the highest frequency of the G1862T mutation, which differed signifi cantly (p = 0.027) between the subgenotypes A1 and A2 because this mutation was present only in samples from patients infected with A1. Thus, HBV genotype A was characterized by a higher frequency of the A1762T/G1764A and G1862T mutations and a lower frequency of the G1899A mutation compared with the other genotypes. A cytosine was found at position 1858 in 78.6% of the infected samples with genotype A. However, a thymine at this same position was found in two samples infected with subgenotype A1, which did not have any of the mutations described in this work. However, one sample classifi ed as A2 had a T at position 1858 and carried the A1762T/G1764A and G1899A mutations. None of the patients infected with the HBV genotype A carried the G1896A mutation. Genotype C was characterized by a higher frequency of the A1762T/G1764A mutation and an intermediate frequency of the G1896A and G1899A mutations, whereas none of the patients carried the G1862T mutation. Genotype D had a higher frequency of the G1896A mutation, an intermediate frequency of the A1762T/ G1764A and G1899A mutations, and a low frequency of the G1862T mutation. The presence of a T at position 1858 was specifi c for genotypes C and D, and an intermediate frequency of the T1753V mutation was observed in all genotypes (Table 1) .
Precore/core mutations and HBeAg status
Eight (14.8%) of the 54 patients were HBeAg positive, and 46 (85.2%) patients were HBeAg negative. When comparing this qualitative variable with the mutations identifi ed in the BCP and precore/core gene regions, signifi cant differences were observed compared with the G1896A stop codon mutation (p< 0.001). All 30 samples identifi ed as G1896A mutants were HBeAg negative and corresponded to 65.2% (30/46) of HBeAg-negative patients. Of the other 16 HBeAg negative samples, three (18.8%) had the double mutation (A1762T/G1764A) plus the T1753V and the G1862T mutations, three (18.8%) had the G1862T mutation and the double mutation, three (18.8%) others did not have any of the mutations analyzed in this study, two (12.5%) had only the double mutation, one (6.2%) sample had the T1753V mutation plus theA1762T/G1764A and G1899A mutations, one (6.2%) had the double and the T1753V mutations, one (6.2%) had the double and the G1899A mutation, and one (6.2%) had only the G1899A mutation. One (6.2%) sample had the G1862T mutation but was found to contain a mutation at position 1814 substituting A for C, which altered the start codon of the precore gene leading to the loss of HBeAg translation. None of the HBeAg-positive patients carried the G1896A stop codon mutation in the precore gene.
In genotype D, 32/36 (89%) samples were classifi ed as HBeAg negative and 28/36 (77.7%) as G1896A mutants. Signifi cant differences were observed when comparing these two variables (HBeAg x G1896A) among the genotype D sequences (p= 0.001).
A signifi cant difference (p = 0.030) was also observed when comparing HBeAg status and ALT. Elevated ALT levels were more frequent in the HBeAg-positive patients (4/8, 50%) compared with the HBeAg-negative patients (6/46, 13%).
DISCUSSION
In this study, we characterized HBV subgenotypes in relation to demographic, clinical (HBeAg status/ALT levels) and virological (BCP and precore/core mutations) features in patients chronically infected with HBV from the State of Paraná in Southern Brazil. HBV DNA was amplifi ed using primers that anneal in the conserved regions of the HBV genome, and HBV DNA was detected in 79% of the 71 samples studied. This detection frequency is in agreement with the sensitivity values reported in the literature 50, 51 .
The frequency of genotypes A (26%) and D (66.7%) observed here supports the HBV genotyping studies conducted with blood donors from State of Paraná and studies focused on HBV genotype distribution in different regions of southern Brazil, which reported that HBV/D is the most frequent genotype followed by genotype A 19, [52] [53] [54] . The State of Paraná is one of the states with the widest ethnic variety in Brazil. This state was colonized by people from the Mediterranean region (Spanish, Portuguese and Italians) and from the Middle East (Arabs), which explains the high prevalence of genotype D found in the studied region. Colonization from northwestern Europe (Germans, Poles, Ukrainians, and Dutch), in addition to Africans from the time of slavery, explains the presence of genotype A found in this study. Japanese settlement in Brazil likely brought the characteristic genotypes from their region of origin. Thus, genotype C (5.6%) was detected in this study as the patients were from the regions in State of Paraná with a large number of immigrants from Asian countries. In this respect, Maringá possesses one of the largest Japanese colonies in the State of Paraná (http://www.parana.pr.gov.br/etnias). According to the literature, genotype C is characteristically found in Asia. More specifi cally, subgenotype C2, the only subgenotype of genotype C detected in the present study, is commonly found in Far Eastern countries, including Japan, China and Korea 55, 56 . The only patient infected with genotype E was from GuineaBissau, a country on the western coast of Africa where this genotype is primarily found 57 . The frequencies of genotypes A and D found in this study are similar to the frequencies reported by Lindh et al. 58 for southern Europe where genotype A was detected in 15% of patients and genotype D in 85% of patients. Similar fi ndings have been reported for northern Africa where genotype D is the most prevalent, but the frequency of genotype A is also signifi cant 56 . Genotype D as well as its subgenotypes (D1, D2 and D3) is found worldwide but shows a high prevalence in the Mediterranean region, including the Middle East 12, 21 . In Europe, genotype D is found in the southern countries that border the Mediterranean Sea and accounts for nearly 100% of the HBV cases found in Greece, Italy, Serbia and Albania 59 . Based on European published data, HBV/D3 is most prevalent in Italy with a frequency of 40.4% (72.7% of HBV/D) 60 . Two subgenotypes of genotype A were identifi ed in the present study: A2, which is prevalent in Europe, and A1, which is prevalent in Africa and Asia 61 . Thus, the presence of genotypes A, C and D and their respective subgenotypes A1, A2, C2, D1, D2 and D3 in the investigated population refl ects the immigration that has been occurring in the studied region. State of Paraná specifi cally received large numbers of Italian and German immigrants, and most of its population is descended from people from these nations 62 . Analysis of the patients as a whole showed no signifi cant difference in clinical characteristics between the three main genotypes 1, 63 .
Comparison of the HBV virological characteristics between genotypes A, C and D revealed signifi cant differences in terms of the G1896A and G1862T mutations and the presence of a thymine at position 1858. A higher (77.7%) frequency of the G1896A stop codon mutation was observed in genotype D, and this mutation showed signifi cant association with HBeAg status as all G1896A mutants were HBeAg negative. Genotype D was the most frequent genotype (69.5% -32/46) in HBeAgnegative patients; therefore, a signifi cant difference in the frequency of the G1896A mutation was observed between HBeAg-negative and -positive samples belonging to genotype D. This fi nding suggests that this mutation is one of the most important factors for early seroconversion of HBeAg. These fi ndings are in agreement with Elkady et al. 64 who studied mutations in patients infected with genotype D. All genotype D and C sequences, including HBeAg-negative and -positive samples, had a thymine (T) at position 1858, which confers stability to the stem-loop structure of the encapsidation signal in the presence of the G1896A mutation due to base pairing between these positions 35, 65 .
In contrast to genotypes C and D, genotype A sequences did not harbor the G1896A mutation, which is likely due to the presence of a cytosine (C) at position 1858 in 78.6% of the sequences. The G1896A mutation is unfavorable in this case as base pairing in the precore pregenomic ribonucleic acid (RNA) is essential for the maintenance of viral replication 24, 61, 66, 67 . Similar results regarding the nucleotide present at position 1858 in each genotype have been reported by Chandra et al. 67 , who observed the presence of a cytosine at this position in 88% of genotype A samples and the presence of a thymine in 96% of genotype C and 100% of genotype D samples. The presence of a C at position 1858 is primarily found in genotype A and is frequent in subgenotype C1 but not C2 10, 68 .
Analysis of the HBeAg status and serum ALT levels showed a signifi cant difference, with the frequency of elevated ALT levels being higher among HBeAg-positive patients (50%) and lower (13%) among HBeAg-negative patients. In addition, similar results have been reported by Kidd-Ljunggren et al. 50 . When the patients were analyzed for signs of viral replication, the authors observed that HBeAg-positive patients were more likely than anti-HBe-positive patients to have elevated ALT levels (55% and 24%, respectively). This result is an interesting fi nding in the context of immunotolerance, which is believed to exist during the HBeAg-positive phase because elevated ALT levels suggest an immunoreactive state rather than a state of tolerance by the immune system 50 .
In the present study, a significant difference in the distribution of the G1862T mutation was observed between genotypes. Patients infected with subgenotype A1 had the highest frequency (82% -9/11) followed by the patients infected with genotype D (18% -2/11). None of the samples belonging to subgenotype A2 or genotype C harbored this mutation. Similar results have been reported by Chandra et al. 67 and Tanaka et al. 69 . According to the latter authors, the subgenotypes of genotype A are known to infl uence the prevalence of G1862T. In contrast, Chandra et al. 67 reported that the G1862T mutation is rare in subgenotype A2 but is common in A1. In addition, these authors did not detect the G1862T mutation in genotype C, which was also observed in the present study. Guarnieri et al. 30 proposed that the G1862T mutation contributes to the reduced replication capacity of genotype A and that the G1899A mutation relieves the inhibitory effect of G1862T on genome replication by restoring core protein expression. However, no signifi cant difference in the frequency of the G1899A mutation between genotypes was observed in the present study with the observation of an intermediate frequency in genotypes C and D and a low (7.1%) frequency in genotype A.
No signifi cant difference in the frequency of the A1762T/ G1764A BCP mutation was observed between genotypes in this study. However, statistical analysis revealed a result close to signifi cance, which has been reported in other studies 25, 50 . The frequency of this double mutation in the BCP gene was higher in genotypes C and A (66.7% and 64.3%, respectively). The lowest frequency was observed among patients infected with genotype D (30.5%), which is in agreement with other investigators 64, 67, 69 . The result may have been signifi cant if a larger sample size was achieved. The frequency of the T1753V mutation, which is also located in the BCP region, did not differ signifi cantly between genotypes with the observation of an intermediate and similar frequency. These two mutations in the BCP gene have been reported as risk factors for the development of HCC, and our results show that the virus is primarily mutant at both positions 1, 35, 36, 63, 64 . The present study found that 14.8% of patients were HBeAg positive and identifi ed HBV genotypes A, C, D and E and subgenotypes A1, A2, D1, D2, D3 and C2 in chronic carriers circulating in the southern region of Brazil. No differences in the clinical characteristics of infected patients were observed between genotypes. However, a signifi cant difference was observed when comparing HBeAg status and the presence of the G1896A stop codon mutation in patients infected with genotype D (D1, D2 and D3). Most patients carrying this mutation were anti-HBe positive, which demonstrates the existence of a relationship between the HBV G1896A precore mutant and genotype D in HBeAg seroconversion. Analysis of the mutations showed a well-defi ned distribution according to genotype. Specifi cally, a higher prevalence of the G1896A mutation and the presence of a thymine at position 1858 were observed in genotype D samples, whereas genotype A was associated with a higher prevalence of the G1862T and a C at position 1858. Although the difference in the distribution of the A1762T/G1764A mutation between genotypes was not signifi cant, the mutation was more prevalent in genotypes A and C than genotype D. A correlation between HBV genotypes and mutations in the BCP and precore/core region was shown, demonstrating that these analyses combined with the detection of HBeAg-positive patients are important tools and essential for the prognosis and treatment of patients with chronic HBV because they are associated with increased risk for the development of HCC. Studies focused on clinical and virological monitoring of larger numbers of patients with chronic HBV are needed to gain a better understanding of HBV disease. 
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